Javier Limon-Casas
Alcorcon, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Rimegepant for migraine prevention in clinical practice: A multicenter study including patients with prior anti-CGRP monoclonal antibody failure (GEMA project).
Journal: Cephalalgia : an international journal of headache
Published: July 06, 2026
Atogepant for migraine in real-world clinical practice: Insights from a large multicentre study in a treatment-resistant population (GEMA project).
Journal: Cephalalgia : an international journal of headache
Published: April 01, 2026
ESTELA-Study: Long-Term Effectiveness and Safety of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies in Real-World Clinical Practice.
Journal: Brain and behavior
Published: February 13, 2026
Atogepant after anti-CGRP monoclonal antibodies failure in migraine: a multicenter real-world study of effectiveness, safety, persistence and predictors of response.
Journal: The journal of headache and pain
Published: October 31, 2025
Evaluation of the effectiveness and safety of anti-CGRP monoclonal antibodies in patients with migraine and autoimmune diseases: IMMUNO-CGRP study.
Journal: Headache
Published: September 06, 2025
Unravelling Migraine Stigma: A Comprehensive Review of Its Impact and Strategies for Change.
Journal: Journal of clinical medicine
Published: July 22, 2024
Long-term safety of OnabotulinumtoxinA treatment in chronic migraine patients: a five-year retrospective study.
Journal: Frontiers in neurology
Published: April 15, 2024
Real-world experience of OnabotulinumtoxinA treatment in female patients with chronic migraine: a qualitative study using in-depth interviews.
Journal: Annals of medicine
Published: September 14, 2023
Evaluation of the concomitant use of prophylactic treatments in patients with migraine under anti-calcitonin gene-related peptide therapies: The PREVENAC study.
Journal: European journal of neurology
Published: August 30, 2023
Effectiveness, tolerability, and response predictors of preventive anti-CGRP mAbs for migraine in patients over 65 years old: a multicenter real-world case-control study.
Journal: Pain medicine (Malden, Mass.)
Published: August 02, 2023
Machine-learning-based approach for predicting response to anti-calcitonin gene-related peptide (CGRP) receptor or ligand antibody treatment in patients with migraine: A multicenter Spanish study.
Journal: European journal of neurology
Published: May 25, 2022
Last Updated: 09/26/2026